Senkina et al. (Abstract)
Cellular Therapy and Transplantation (CTT), Vol. 2, No. 5, 2009
doi: 10.3205/ctt-2009-No5-abstract76
© The Authors. This abstract is provided under the following license:
Creative Commons Attribution 3.0 Unported
Abstract accepted for "Joint EBMT Pediatric Working Party – 3rd Raisa Gorbacheva Memorial Meeting on Hematopoietic Stem Cell Transplantation", Saint Petersburg, Russia, September 17–20, 2009
Association between HLA class I antigens and survival length in patients with multiple myeloma
Elena A. Senkina, Galina A. Zaitseva, Tamara P. Zagoskina, Konstantin A. Martynov
FSE Kirov Research Institute of Hematology and Blood Transfusion of FMBA of Russia, Kirov, Russia
Correspondence: Elena A. Senkina, FSE Kirov Research Institute of Hematology and Blood Transfusion of FMBA of Russia, Krasnoarmeyskaya str., 72, Kirov, 610027, Russia, Phone: +7 (8332) 54-51-83, Phone/Fax: +7 (8332) 54-97-31, E-mail: immunlab@yandex.ru
Abstract
Aim: The aim of the investigation was to determine the association between human leukocyte antigens (HLA) class I phenotype and the length of survival in patients with multiple myeloma.
Methods: HLA class I (loci A and B) antigens were tested using the standard lymphocytotoxicity test with reagents produced by “Gisans”, St. Petersburg. The HLA phenotype was identified in 120 patients with multiple myeloma. There were 53 (41.2%) males and 67 (55.8%) females among them. The median age at diagnosis was 60 years. The diagnosis of multiple myeloma was established according to standard criteria. Patients received the following chemotherapy programs: MP, M2, VAD, and PAD. Survival was calculated from the date of diagnosis using curves Kaplan-Meier (“Statistica 6.0”). Survival lengths of patient groups were compared using the log-rank method (“Biostat”).
Results: A statistically significant difference was obtained in the comparison of survival curves of patients with HLA-B5 and without (p<0.05). Patients who had HLA-B5 in their HLA phenotype, had a higher risk of death than others, with a median survival length of 29 months compared to 79 months.
Conclusion: Poor prognosis and low survival length in patients with multiple myeloma are associated with HLA-B5.
Keywords: multiple myeloma, HLA, survival
<-- Previous abstract Contents Next abstract -->
